13F Holdings
中文EN

TTRX Turn Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2023016 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-236.5%
TTM EPS YoY-186.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-412.3%
ROA-123.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets65.2%
Debt / equity1.09x
Current ratio3.19x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.41x
Accruals ratio-72.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$265,570$245,956
SG&A expense$5.59M$1.55M
Operating income-$5.86M-$1.80M
Net income-$3.19M-$1.77M
EBITDA-$5.81M-$1.75M
EPS (basic)-0.12-0.07
EPS (diluted)-0.12-0.07
Weighted avg. shares (diluted)27.72M26.64M
Balance sheet
Cash & equivalents$4.03M$872,599
Current assets$5.20M$1.10M
Intangibles$922,171$821,931
Total assets$12.16M$2.05M
Current liabilities$6.00M$707,932
Total liabilities$7.48M$2.23M
Shareholders' equity$4.69M-$177,432
Shares outstanding29.45M26.85M
Cash flow statement
Operating cash flow-$2.56M-$1.36M
Investing cash flow-$152,986-$99,475
Financing cash flow$6.92M$1.15M
Depreciation & amortization$52,746$47,483
Stock-based compensation$419,245$352,833

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.